Mallinckrodt Public Limited Company (MNK) EPS Estimated At $1.49

July 13, 2018 - By Ash

Investors sentiment increased to 0.9 in 2018 Q1. Its up 0.19, from 0.71 in 2017Q4. It increased, as 38 investors sold Mallinckrodt Public Limited Company shares while 85 reduced holdings. 47 funds opened positions while 64 raised stakes. 96.44 million shares or 6.30% more from 90.73 million shares in 2017Q4 were reported.
Pomelo Ltd Llc stated it has 72,245 shares. Van Eck Associate holds 129,464 shares. Louisiana State Employees Retirement System has 22,700 shares. Hudock Cap Grp Inc Lc invested in 35 shares. Aqr Capital Mngmt Llc invested in 0% or 35,034 shares. Teacher Retirement Systems Of Texas owns 21,040 shares. Morgan Stanley owns 664,543 shares. Kbc Gru Nv stated it has 0.02% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Tower Rech Capital Ltd Llc (Trc) stated it has 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). Swiss Financial Bank accumulated 168,900 shares or 0% of the stock. First Quadrant Ltd Partnership Ca accumulated 103,440 shares. 532,707 were reported by Parametric Port Ltd Liability. Peak6 Invests Limited Partnership has invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK). First Bank & Trust Of Omaha reported 58,663 shares. Cibc World Incorporated invested 0% of its portfolio in Mallinckrodt Public Limited Company (NYSE:MNK).

Since May 9, 2018, it had 1 insider buy, and 1 insider sale for $4.14 million activity. Flynn James E also sold $4.19M worth of Mallinckrodt Public Limited Company (NYSE:MNK) on Wednesday, May 9.

Analysts expect Mallinckrodt Public Limited Company (NYSE:MNK) to report $1.49 EPS on August, 7 before the open.They anticipate $0.36 EPS change or 19.46 % from last quarter’s $1.85 EPS. MNK’s profit would be $123.79 million giving it 3.61 P/E if the $1.49 EPS is correct. After having $1.31 EPS previously, Mallinckrodt Public Limited Company’s analysts see 13.74 % EPS growth. The stock increased 2.62% or $0.55 during the last trading session, reaching $21.51. About 2.80M shares traded. Mallinckrodt Public Limited Company (NYSE:MNK) has declined 59.76% since July 13, 2017 and is downtrending. It has underperformed by 72.33% the S&P500.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Coverage

Among 12 analysts covering Mallinckrodt (NYSE:MNK), 3 have Buy rating, 1 Sell and 8 Hold. Therefore 25% are positive. Mallinckrodt had 20 analyst reports since February 2, 2018 according to SRatingsIntel. Mizuho maintained Mallinckrodt Public Limited Company (NYSE:MNK) on Tuesday, February 27 with “Hold” rating. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) earned “Buy” rating by Jefferies on Tuesday, February 27. Barclays Capital downgraded the stock to “Underweight” rating in Friday, February 2 report. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) has “Buy” rating given on Tuesday, February 27 by Cantor Fitzgerald. The stock of Mallinckrodt Public Limited Company (NYSE:MNK) has “Hold” rating given on Friday, May 18 by Mizuho. The stock has “Hold” rating by Mizuho on Friday, March 9. On Monday, April 23 the stock rating was maintained by Leerink Swann with “Hold”. The firm has “Hold” rating by Mizuho given on Thursday, April 26. The stock has “Market Perform” rating by Wells Fargo on Monday, July 9. The company was maintained on Tuesday, March 6 by Canaccord Genuity.

Mallinckrodt public limited company develops, makes, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company has market cap of $1.79 billion. The company's Specialty Brands segment markets branded pharmaceutical products for autoimmune and rare diseases, including the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and hemostasis products, and central nervous system drugs. It has a 1.17 P/E ratio. This segment offers Acthar, an injectable drug for various indications, such as neurology, rheumatology, nephrology, and pulmonology; Ofirmev, an intravenous formulation of acetaminophen for pain management; Inomax for inhalation; Therakos, an immunotherapy treatment platform; and Exalgo, a form of hydromorphone.

Another recent and important Mallinckrodt Public Limited Company (NYSE:MNK) news was published by Seekingalpha.com which published an article titled: “S&P 1500 Misfit Stocks” on July 06, 2018.

Mallinckrodt Public Limited Company (NYSE:MNK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>